文献速递其他结缔组织病

托珠单抗皮下给药方案在全身型或多关节型幼年特发性关节炎患儿中的应用

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

两项52周1b期试验评估皮下托珠单抗(s.c.-TCZ)在全身型JIA(sJIA)和多关节型JIA(pJIA)患儿中的给药方案,主要终点为药代动力学、药效动力学和安全性。s.c.-TCZ暴露与风险/获益特征与静脉给药相似,为患者和照护者提供了更便捷的替代给药途径。

要点

  • s.c.-TCZ可使96% sJIA和100% pJIA患者稳态谷浓度超过i.v.-TCZ第5百分位。
  • 第52周sJIA和pJIA临床缓解率分别为53%和31%,JADAS-71改善与i.v.-TCZ相当。
  • 注射部位反应发生率sJIA 41.2%、pJIA 28.8%,安全性总体与i.v.-TCZ一致。

核心结论

  • s.c.-TCZ提供的暴露和风险/获益特征与i.v.-TCZ相似。
  • 皮下给药为患者和照护者提供了更便捷的替代途径,具有居家使用潜力。

研究设计与样本

  • 两项52周1b期试验,sJIA患者每周或每2周(中期分析前每10天)接受s.c.-TCZ 162 mg/剂。
  • pJIA患者体重≥30 kg每2周、<30 kg每3周接受s.c.-TCZ 162 mg/剂。
  • 共51例sJIA和52例pJIA患者,年龄1-17岁,与i.v.-TCZ 3期试验数据比较。

主要发现

  • 49例(96%)sJIA和52例(100%)pJIA患者达到稳态谷浓度>i.v.-TCZ第5百分位。
  • 两个人群中不同体重组的药效动力学疾病标志物相似。
  • s.c.-TCZ与i.v.-TCZ的幼年关节炎疾病活动评分-71(JADAS-71)改善相当。
  • 第52周53% sJIA和31% pJIA患者达到临床缓解(on treatment)。
  • 注射部位反应报告率sJIA 41.2%、pJIA 28.8%;感染报告率分别为78.4%和69.2%。

关键数值与推荐

  • s.c.-TCZ剂量为162 mg/剂,sJIA每周或每2周给药,pJIA按体重≥30 kg每2周、<30 kg每3周给药。
  • 主要终点为药代动力学、药效动力学和安全性,疗效为探索性终点。
  • 2例sJIA患者死亡,均认为与TCZ相关。

临床怎么用

  • s.c.-TCZ可作为sJIA和pJIA患者替代i.v.-TCZ的给药途径,便于居家使用。
  • 用药期间需关注注射部位反应和感染风险,并警惕与TCZ相关的严重不良事件。

局限性

  • 疗效为探索性终点,非主要终点。
  • 样本量较小(sJIA 51例、pJIA 52例),且为非对照1b期试验。
  • 与i.v.-TCZ 3期试验数据为跨试验比较,非头对头随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine s.c. tocilizumab (s.c.-TCZ) dosing regimens for systemic JIA (sJIA) and polyarticular JIA (pJIA). METHODS: In two 52-week phase 1 b trials, s.c.-TCZ (162 mg/dose) was administered to sJIA patients every week or every 2 weeks (every 10 days before interim analysis) and to pJIA patients every 2 weeks or every 3 weeks with body weight ≥30 kg or <30 kg, respectively. Primary end points were pharmacokinetics, pharmacodynamics and safety; efficacy was exploratory. Comparisons were made to data from phase 3 trials with i.v. tocilizumab (i.v.-TCZ) in sJIA and pJIA. RESULTS: Study participants were 51 sJIA patients and 52 pJIA patients aged 1-17 years who received s.c.-TCZ. Steady-state minimum TCZ concentration (Ctrough) >5th percentile of that achieved with i.v.-TCZ was achieved by 49 (96%) sJIA and 52 (100%) pJIA patients. In both populations, pharmacodynamic markers of disease were similar between body weight groups. Improvements in Juvenile Arthritis DAS-71 were comparable between s.c.-TCZ and i.v.-TCZ. By week 52, 53% of sJIA patients and 31% of pJIA patients achieved clinical remission on treatment. Safety was consistent with that of i.v.-TCZ except for injection site reactions, reported by 41.2% and 28.8% of sJIA and pJIA patients, respectively. Infections were reported in 78.4% and 69.2% of patients, respectively. Two sJIA patients died; both deaths were considered to be related to TCZ. CONCLUSION: s.c.-TCZ provides exposure and risk/benefit profiles similar to those of i.v.-TCZ. S.c. administration provides an alternative administration route that is more convenient for patients and caregivers and that has potential for in-home use. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT01904292 and NCT01904279.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ruperto N, Brunner HI, Ramanan AV, et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021. PMID: 33506875. doi:10.1093/rheumatology/keab047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。